ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD. Lead compound ONL1204 is entering a Phase 2 study in Retinal Detachment and preparing for Phase 2 studies in Geographic Atrophy/Dry AMD and Open-angle Glaucoma.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Michigan
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Ophthalmology
Lead Product in Development:
ONL1204
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
